Loss‐of‐function mutations of PBRM1 were recently discovered to be associated with response to checkpoint inhibition therapies in ccRCC patients treated with anti‐PD‐1 alone or in combination with anti‐CTLA‐4 therapies (Miao et al., 2018). Here, PBRM1 is linked to nonpapillary renal cell carcinoma.